MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Revenue 2011-2026 | CALT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 874 K | 185 M | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 874 K | 92.9 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 18.41 | -1.02 % | $ 118 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
272 M | $ 36.73 | 3.67 % | $ 1.35 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 3.14 | 2.28 % | $ 44.1 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.53 | 0.4 % | $ 1.33 B |  Canada |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.35 | 1.71 % | $ 1.95 B | Canada |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.43 | 1.78 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.04 | 4.83 % | $ 112 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.39 | 5.75 % | $ 315 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 23.25 | 3.2 % | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
297 M | $ 4.09 | 0.25 % | $ 264 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.39 | 6.88 % | $ 430 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.39 | 1.46 % | $ 402 M | Canada |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 7.01 | 3.85 % | $ 277 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.36 | 3.82 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 1.0 | 3.87 % | $ 49.9 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.29 | 3.62 % | $ 2.84 M | USA |
 |
Tilray
TLRY
|
627 M | $ 6.75 | 4.49 % | $ 4.17 B | Canada |
 |
Veru
VERU
|
16.9 M | $ 2.55 | 2.82 % | $ 344 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 13.57 | 3.12 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.7 | -0.19 % | $ 3.02 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 0.94 | -1.12 % | $ 33.8 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.62 | 1.57 % | $ 2.66 M |  China |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.05 | 1.49 % | $ 23.7 M | USA |